A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.

[1]  Hyo Song Kim,et al.  Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer , 2011, Cancer Chemotherapy and Pharmacology.

[2]  Jianming Xu,et al.  The Sequence-Dependent Cytotoxic Effect of Trastuzumab in Combination With 5-Fluorouracil or Cisplatin on Gastric Cancer Cell Lines , 2010, Cancer investigation.

[3]  S. Tanabe,et al.  Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy , 2010, Gastric Cancer.

[4]  M. Yashiro,et al.  Establishment and characterization of multidrug-resistant gastric cancer cell lines. , 2010, Anticancer research.

[5]  M. Katoh.  FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer pathologies. , 2009, The Journal of investigative dermatology.

[6]  M. Yashiro,et al.  Synergistic antitumor effects of FGFR2 inhibitor with 5‐fluorouracil on scirrhous gastric carcinoma , 2009, International journal of cancer.

[7]  B. O'Malley,et al.  Cytotoxicity and antiangiogenesis by fibroblast growth factor 2–targeted Ad‐TK cancer gene therapy , 2009, The Laryngoscope.

[8]  M. Katoh,et al.  FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review). , 2009, International journal of molecular medicine.

[9]  A. Lokshin,et al.  Chemotherapeutic drugs and human tumor cells cytokine network , 2008, International journal of cancer.

[10]  P. Pollock,et al.  Brivanib Alaninate, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Tyrosine Kinases, Induces Growth Inhibition in Mouse Models of Human Hepatocellular Carcinoma , 2008, Clinical Cancer Research.

[11]  J. Hoeijmakers,et al.  ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair , 2008, Molecular and Cellular Biology.

[12]  G. Citro,et al.  Cell-cycle molecules in mesothelioma: an overview. , 2007, Journal of experimental & clinical cancer research : CR.

[13]  M. Yashiro,et al.  A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. , 2007, European journal of cancer.

[14]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[15]  C. Allen,et al.  Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[16]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Yashiro,et al.  A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. , 2006, Gastroenterology.

[18]  R. Hitt,et al.  DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Yashiro,et al.  Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma , 2006, Cancer science.

[20]  L. Mariani,et al.  Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition , 2006, Tumori.

[21]  L. Cavanna,et al.  Oxaliplatin in Combination With 5-Fluorouracil (5-FU) and Leucovorin (LV) in Patients With Metastatic Gastric Cancer (MGC) , 2006, American journal of clinical oncology.

[22]  N. Sebire,et al.  FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. , 2006, The EMBO journal.

[23]  Neil J. Sebire,et al.  FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2 , 2006 .

[24]  A. Kimchi,et al.  The death-associated protein kinases: structure, function, and beyond. , 2006, Annual review of biochemistry.

[25]  M. Caraglia,et al.  Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer , 2005, Cancer Chemotherapy and Pharmacology.

[26]  D. Ambrosetti,et al.  Mechanisms underlying differential responses to FGF signaling. , 2005, Cytokine & growth factor reviews.

[27]  D. Harpole,et al.  High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer , 2005, Clinical Cancer Research.

[28]  E. Rubin,et al.  Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  J. G. Park,et al.  Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. , 2001, Cancer research.

[30]  Y. Chung,et al.  Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. , 1995, British Journal of Cancer.

[31]  K. Mafune,et al.  Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer. , 1994, Anticancer research.

[32]  A. Ohtsu,et al.  An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer. , 1991, Japanese journal of clinical oncology.

[33]  O. Dalesio,et al.  cis-Platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC Gastrointestinal Tract Cancer Cooperative Group. , 1985, European journal of cancer & clinical oncology.

[34]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[35]  J. Ajani,et al.  Recent Developments in Oral Chemotherapy Options for Gastric Carcinoma , 2012, Drugs.

[36]  K. Deniz,et al.  Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. , 2010, Asian Pacific journal of cancer prevention : APJCP.

[37]  E. Van Cutsem,et al.  Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. , 2008, European journal of cancer.

[38]  J. Hoeijmakers,et al.  ERCC 1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair † , 2008 .

[39]  S. Kang,et al.  Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. , 2008, Lung cancer.

[40]  櫻井 克宣.  A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver , 2007 .

[41]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[42]  I. Choi,et al.  Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. , 2004, Japanese journal of clinical oncology.

[43]  G. Fountzilas,et al.  Paclitaxel and carboplatin in pretreated advanced gastric cancer: a phase II study. , 2002, Oncology reports.